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Original Article

Ovarian cancer modulates the
immunosuppressive function of CD11bþGr1þ
myeloid cells via glutamine metabolism
Mary P. Udumula 1, 9, Sharif Sakr 2, 9, 10, Sajad Dar 1, 11, Ayesha B. Alvero 3, Rouba Ali-Fehmi 4,
Eman Abdulfatah 4, 12, Jing Li 5, Jun Jiang 5, Amy Tang 6, Thomas Buekers 1, 2, Robert Morris 2,
Adnan Munkarah 1, Shailendra Giri 7, Ramandeep Rattan 1, 8, *
ABSTRACT
Objective: Immature CD11b þ Gr1þ myeloid cells that acquire immunosuppressive capability, also known as myeloid-derived suppressor cells
(MDSCs), are a heterogeneous population of cells that regulate immune responses. Our study’s objective was to elucidate the role of ovarian
cancer microenvironment in regulating the immunosuppressive function of CD11bþGr1þ myeloid cells.
Methods: All studies were performed using the intraperitoneal ID8 syngeneic epithelial ovarian cancer mouse model. Myeloid cell depletion and
immunotherapy were carried out using anti-Gr1 mAb, gemcitabine treatments, and/or anti-PD1 mAb. The treatment effect was assessed by a
survival curve, in situ luciferase-guided imaging, and histopathologic evaluation. Adoptive transfer assays were carried out between congenic
CD45.2 and CD45.1 mice. Immune surface and intracellular markers were assessed by ﬂow cytometry. ELISA, western blot, and RT-PCR
techniques were employed to assess the protein and RNA expression of various markers. Bone marrow-derived myeloid cells were used for
ex-vivo studies.
Results: The depletion of Gr1þ immunosuppressive myeloid cells alone and in combination with anti-PD1 immunotherapy inhibited ovarian
cancer growth. In addition to the adoptive transfer studies, these ﬁndings validate the role of immunosuppressive CD11bþGr1þ myeloid cells in
promoting ovarian cancer. Mechanistic investigations showed that ID8 tumor cells and their microenvironments produced recruitment and
regulatory factors for immunosuppressive CD11bþGr1þ myeloid cells. CD11bþGr1þ myeloid cells primed by ID8 tumors showed increased
immunosuppressive marker expression and acquired an energetic metabolic phenotype promoted primarily by increased oxidative phosphorylation fueled by glutamine. Inhibiting the glutamine metabolic pathway reduced the increased oxidative phosphorylation and decreased
immunosuppressive markers’ expression and function. Dihydrolipoamide succinyl transferase (DLST), a subunit of a-KGDC in the TCA cycle, was
found to be the most signiﬁcantly elevated gene in tumor-primed myeloid cells. The inhibition of DLST reduced oxidative phosphorylation,
immunosuppressive marker expression and function in myeloid cells.
Conclusion: Our study shows that the ovarian cancer microenvironment can regulate the metabolism and function of immunosuppressive
CD11b þ Gr1þ myeloid cells and modulate its immune microenvironment. Targeting glutamine metabolism via DLST in immunosuppressive
myeloid cells decreased their activity, leading to a reduction in the immunosuppressive tumor microenvironment. Thus, targeting glutamine
metabolism has the potential to enhance the success of immunotherapy in ovarian cancer.
Ó 2021 The Author(s). Published by Elsevier GmbH. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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1. INTRODUCTION
Epithelial ovarian cancer (EOC) remains the most lethal gynecologic
cancer in women, yet patient survival has not improved in decades.
Immunotherapy is an attractive therapeutic option for ovarian cancer,
and evidence suggests that it may be a promising alternative to current
therapeutic strategies [1,2]. EOC cells elicit a speciﬁc immune
response and express many tumor-associated antigens, potentially
allowing for susceptibility to immunotherapy [3e5]. High-grade serous
ovarian cancer patients with an immunoreactive subtype of tumors
exhibit improved survival compared to other subtypes [6,7]. Additionally, in EOC patients, the presence of tumor-inﬁltrating lymphocytes
correlates with longer progression-free and overall survival, while the
lack of lymphocytes is associated with poor prognosis [8e11]. Though
promising, the results from clinical trials based on checkpoint inhibitors, vaccines, or adoptive T cell therapy are moderate compared to
the remarkable developments seen in other cancer types [12e14].
Thus, the efﬁcacy of immunotherapy for EOC has shown only limited
improvement in tumor responses or patient survival.
One of the underlying reasons for the limited efﬁcacy of immunotherapy for EOC may be tumor-induced immune suppression [15,16].
Multiple pathways in various cell types inhibit the immune response
against tumors; this includes immune suppression by myeloid-derived
suppressor cells (MDSCs), which are CD11bþGr1þ immature myeloid
cells that persist under conditions of chronic infection, inﬂammation, or
cancer and play a crucial role in potentiating tumor growth [17]. Their
primary function is to suppress various immune responses, especially
regarding T cells. In mice, MDSCs are broadly characterized as
CD11bþGr1þ and consist of two subsets called granulocytic/polymorphonuclear MDSCs (PMN-MDSCs) and monocytic MDSCs (MMDSCs) [18]. PMN-MDSC are similar to neutrophils and are identiﬁed
as CD11bþLy6GþLy6Clo in mice and CD11b þ CD14CD15þ or CD66in humans. However, M-MDSCs are morphologically similar to
monocytes and are recognized as CD11bþLy6GLy6Chi in mice and as
CD11b þ CD14þHLADR/loCD15Lin- in humans [17,18]. Though
PMN-MDSCs and M-MDSCs suppress T cells, they do so via distinct
mechanisms. PMN-MDSCs produce reactive oxygen species and
arginase 1 enzyme, whereas M-MDSCs use nitric oxide synthase 2 and
reactive oxygen species to inhibit T-cells [17,18]. Although MDSCs are
morphologically and phenotypically similar to neutrophils and monocytes, they have a distinct genomic, biochemical, and functional
identity [19,20]. Recently, the similarities between PMN-MDSC and
activated neutrophils have blurred the contribution of each cell type in
cancer. Tumor-associated neutrophils are pro-inﬂammatory, promote
ovarian cancer metastatic niche, and suppress T-cell function [21,22].
As there are no distinct mouse markers to differentiate between
MDSCs and tumor-associated neutrophils, we are using the broad
terminology of immunosuppressive CD11bþGr1þ cells.
Apart from immune suppression, immunosuppressive CD11bþGr1þ
cells can also promote tumor progression by altering the tumor
microenvironment; they can produce pro-angiogenic factors, support
metastasis, promote chemoresistance, enhance stemness, and, in
some cancers, modulate senescence [23e29]. In ovarian cancer,
these immunosuppressive myeloid cells have been shown to enhance
stemness [26], promote angiogenesis and invasion [23], and inﬂuence
the outcome of immunotherapy [30,31]. The increased inﬁltration of
immunosuppressive CD11bþGr1þ cells into tumors was previously
noted in cancer patients and is associated with worse outcomes,
including in ovarian cancer patients [8e11]. These studies demonstrate that immunosuppressive CD11bþGr1þ cells play a critical
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pathological role in altering the immune response against ovarian
cancer, ultimately enabling disease progression. Thus, identifying
mechanisms to target CD11bþGr1þ cells may lead to new therapeutic
strategies.
Emerging evidence strongly support the role of cellular metabolism,
particularly energy metabolism, in regulating the expansion, differentiation, and effector function of various immune cells, including macrophages, T cells, and immunosuppressive CD11bþGr1þ cells [32,33].
Cells produce ATP, the energy currency mainly generated by glycolysis
or oxidative phosphorylation, which are often dysregulated in cancer
cells and immune cells. According to the tumor type, the immunosuppressive function and proliferation of immunosuppressive
CD11bþGr1þ cells have been reported to be regulated by various
energy pathways. The roles of glycolysis, fatty acid oxidation, and
glutaminolysis have been shown in breast cancer, lung and colon
cancer, and breast and lung cancer, respectively [34e40].
In this study, we show that immunosuppressive CD11bþGr1þ myeloid
cells play a role in promoting ovarian cancer growth, and their
depletion augments the effects of immunotherapy. Mechanistically, we
show that the ovarian cancer microenvironment can increase the
immunosuppressive ability of these cells by increasing their metabolic
ﬁtness through an increase in glutamine metabolism. Collectively, our
data provides the framework for developing strategies to target
immunosuppressive CD11bþGr1þ cell metabolism that can be combined with other immunotherapeutic approaches to treat ovarian
cancer.
2. MATERIAL AND METHODS
2.1. Cell lines and reagents
The mouse ovarian surface-epithelial cancer cell line ID8, transduced
with a lentiviral vector expressing ﬁreﬂy luciferase (ID8-luc2), was
kindly provided by Dr. John Liao, University of Washington, Seattle,
WA [41]. The cell line was maintained in RPMI media (HyClone,
Thermo Scientiﬁc, Waltham, MA), supplemented with 10% fetal
bovine serum (BioAbChem, Ladson, SC). For collecting ID8 conditioned media (ID8 CM), 70% conﬂuent cells were given a media
change, which was collected after 48 h. The collected media was
ﬁltered, aliquoted, and frozen until use. Metabolic pathway inhibitors
BPTES [(1Z, 10 Z)-N0 ,N’’-(5,5’-(thiobis (ethane-2,1-diyl))bis (1,3,4thiadiazole-5,2-diyl))bis (2-phenylacetimidic acid)], 2-deoxy glucose
(2-DG), 6-Diazo-5-oxo-L-norleucine (DON), and etomoxir were purchased from Cayman Chemicals (Ann Arbor, Michigan), and 3 methyl
2 oxalo valeric acid (MOV) was purchased from Sigma Aldrich (St
Louis, MO).
2.2. Animal model and experiments
2.2.1. Induction of ovarian cancer
C57/B6 female mice of 6e8 weeks were acquired from Jackson
Laboratory (Bar Harbor, ME) and maintained under standard optimized
conditions in the animal facility at Henry Ford Hospital (Detroit, MI).
Before the start of the study, mice were acclimated to the house for
one week. To induce ovarian cancer, mice were injected intraperitoneally (IP) with 107 ID8-luc2 cells in 200 ml of PBS and were observed
and weighed every other day. At selected time intervals, mice were
imaged to monitor tumor progression. Mice that experienced severe
signs of clinical distress (cachexia, anorexia, or increased respiration)
or had an accumulation of ascites that interfered with mobility or bodily
functions were immediately euthanized [42,43].
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2.2.2. Treatments
All treatments began 10 days after tumor injection, and each treatment
group consisted of 10 mice. Treatments included (i) anti-mouse Ly6G/
Ly6C (anti-Gr-1 mAb) InVivoMab injected IP twice a week at 100 mg/
mouse for 3 weeks; (ii) IgG2b isotype control, anti-keyhole limpet
hemocyanin InVivoMab injected IP twice a week at 100 mg/kg body
weight for 3 weeks; (iii) anti-mouse PD-1 InVivoMab injected intraperitoneally once a week at 100 mg/kg of their body weight for 3
weeks; (iv) gemcitabine injected IP twice a week at 100 mg/kg of body
weight for 6 weeks and (v) vehicle PBS injected IP twice a week at 100
ml/mouse for 6 weeks. All InVivoMabs were purchased from BioX Cell
(West Lebanon, NH). Gemcitabine was procured from Henry Ford
Hospital Pharmacy, Detroit, MI.
2.2.3. Survival Curve
For the survival curve, n ¼ 12 mice per group were injected with ID8
cells to form tumors and allowed to proceed until moribund or their
abdominal circumference reached 9e10 cm, according to the IACUC
approved endpoint. Survival curves were generated using a Kaplane
Meier analysis.
2.2.4. Bioluminescence imaging
Mice received an intraperitoneal injection of D-luciferin (Perkin Elmer)
at 150 mg/kg of body weight (Perkin Elmer, Waltham, MA) 15 min
before imaging while under 1e2% inhaled isoﬂurane anesthesia. The
bioluminescence signals of the tumor were recorded using the
Xenogen IVIS system 2000 series (Perkin Elmer, Akron, Ohio). Images
were acquired over a period of 20 min with a 15s exposure. Living
Image software (Perkin Elmer) was used to read and integrate the total
bioluminescence signals in each region. Bioluminescence measurements were quantiﬁed as total photon ﬂux emission as photons/second
in the images acquired at the same exposure time for the various
groups.
2.2.5. Adoptive transfer
Three sets of 6- to 8-week-old female C57/BL/6 CD45.1 congenic
mice (n ¼ 6/set) and two sets of CD45.2 congenic mice (n ¼ 6/set)
were injected intraperitoneally with 107 ID8-luc2 cells suspended in
200 ml of PBS. After 2 weeks, bone marrow (BM) from CD45.2 congenic mice was used to isolate granulocytic myeloid cells (Gr1hiLy6Gþ;
purity ~92%e94%) and non-granulocytic myeloid cells Gr1-Ly6G;
purity ~92%e94%), using an MDSC isolation kit from Miltenyi Biotech
(Bergisch Gladbach, Germany). The CD45.1 tumor-bearing mice were
separated into three groups; group 1 control did not receive any cells
but saline injections, group 2 received two IV injections of 5  106
puriﬁed granulocytic cells (Gr1þ) a week apart, and group 3 received
two IV injections of 5  106 puriﬁed non-granulocytic (Gr1-) cells a
week apart [44]. Two weeks after the last transfer, mice were imaged
and sacriﬁced for further analysis.
2.2.6. Ex vivo experiments
For all ex vivo experiments, 6- to 8-week-old female C57/B/6 mice
(n ¼ 4) were injected IP with 107 ID8-luc2 cells suspended in 200 ml of
PBS. Two weeks later, Gr1þ cells were isolated from BM using BDIMAG anti-mouse LY6G and LY6C kit (BD Biosciences, San Jose, CA)
[45], counted and used for various assays like Seahorse and
ﬂuorescence-activated cell sorting.
2.3. Targeted metabolomics
Granulocytic myeloid cells (Gr1þ; purity ~92%e94%) were isolated
using a BD-IMAG anti-mouse LY6G and LY6C kit (BD Biosciences, San

Jose, CA) from the BM of naïve and ID8-luc2 tumor-bearing mice at 2
weeks (n ¼ 4/group). Cells were counted, snap-frozen in liquid nitrogen, and stored at 80  C until analysis. Metabolites were
extracted using 80% methanol, as previously described [46]. Cellular
concentrations of metabolites (normalized to cellular protein concentration) were quantitatively determined using an LC-MS/MS-based
targeted metabolomics platform that is capable of quantitatively
proﬁling ~ 250 metabolites, as previously described [46]. As described
previously [47], data analysis was performed using the MetaboAnalyst
4.0 (www.MetaboAnalyst.ca). Features (metabolites) with >20%
missing values (i.e., below the lower limit of quantitation) were
removed from the analysis, while the remaining missing values were
replaced by 1/5 of the minimum value of a feature. To meet the
normality assumption, individual metabolite concentrations were logtransformed and then auto-scaled (mean-centered and divided by
the standard deviation of each metabolite). Unsupervised principal
component analysis (PCA) was performed to visualize the separation of
global metabolic proﬁles between myeloid cells from naïve and tumorbearing mice. We used SAM (Signiﬁcance Analysis of Microarray and
Metabolites) to determine the most signiﬁcant metabolites. A false
discovery rate (FDR; i.e., adjusted p-value) of <0.05 was considered
statistically signiﬁcant. Pathway analysis with the signiﬁcantly changed
metabolites was performed to identify the key metabolic pathways
involved.
2.3.1. Ethics statement
All protocols were approved by the Henry Ford Hospital Institutional
Animal Care and Use Committee before any experiments. All institutional and national guidelines for the care and use of laboratory animals were followed.
2.4. Fluorescence-activated cell sorting analysis
For surface marker staining, lymphocytes from tumors, ascites, blood,
BM, or spleens were incubated with ﬂuorochrome-conjugated antibodies to CD3, CD4, CD8, CD1d, CD16, CD11b, Ly6C, Ly6G, and Gr1 at
the manufacturer’s recommended dilution for 30 min at 4  C, as before
[45]. To analyze intracellular markers like IFNg, lymphocytes were
treated with GolgiPlug (BD Biosciences, San Jose, CA) for 5 h, followed
by surface staining with monoclonal antibodies against CD4 or CD8.
Cells were washed, ﬁxed, and permeabilized with a cytoﬁx/cytoperm
buffer, followed by incubation with an antibody to detect intracellular
levels of IFN-g. Flow cytometric analysis was performed on a BD FACS
Calibur (BD Biosciences), and results were analyzed using FACS Diva
software (BD Biosciences). Fluorochrome labeled antibodies to antimouse CD4 (clone RM4-5), CD8 (clone 53e6.7), CD11b (clone M1/
70), Ly6G (clone 1A8), Ly6C (clone HK1.4), CD45 (clone 30-F11),
CD45.1 (clone A20) and CD45.2 (clone 104) were purchased from
Biolegend (San Diego, CA). Anti-Gr1 (clone RB6-8C5), CD3 (clone
500A2), and IFN-g (clone XMG1.2) were purchased from BD Biosciences. Antibody details are given in Table S1.
2.5. In vitro T cell suppression assay
CD4 T cells were isolated (more than 92% purity) from the spleen by
negative selection using a MojoSort mouse CD4 T cell isolation kit
(Biolegend) and labeled with CFSE (carboxyﬂuorescein diacetate,
succinimidyl ester; 5 mM), as described by the manufacturer (Biolegend). GR1þ cells were isolated from the BM of mice harboring ID8
tumors for two weeks using a BD-IMAG anti-mouse LY6G and LY6C kit
(>94% purity), in accordance with the manufacturer’s instructions (BD
Biosciences, San Jose, CA). For the inhibitor studies, isolated MDSCs
were pretreated with the respective inhibitor 48h prior to co-culture.
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Isolated MDSC and CD4 cells were co-cultured at various ratios from
1:1 to 1:10 in 96-well plates coated with anti-CD3 and anti-CD28
antibodies (1 mg/ml). After 72 h, cells were stained for surface
markers and intracellular cytokines and analyzed by ﬂow cytometry, as
described above [45].
2.6. Ex vivo bone marrow assays
BM cells ﬂushed from the femur and tibia were plated in complete
RPMI-1640 (RPMI-1640 includes 10% FBS and 20 mM penicillin/
streptomycin) media. For differentiating into myeloid cells, cells were
either treated with GM-CSF (20 ng/ml) and IL 6 (10 ng/ml) alone or in
the presence of 30% ID8 CM. On day 8, cells were harvested, and
GR1þ cells were isolated using an anti-mouse LY6G and LY6C kit
according to the manufacturer’s instructions (BD Biosciences, San
Jose, CA). The purity of the isolated cell populations was determined by
ﬂow cytometry, and the frequency of CD11bþGr1þ cells was >95%.
The differentiated BM-MDSCs were treated with indicated inhibitors for
24e48 h. For glutamine deprivation, differentiated BM cells were
plated in a low glutamine medium (0.5 mM) or the regular RPMI media
containing 2 mM glutamine for 48 h before use for assays.

was used as a housekeeping gene. All the primers were purchased
from Integrated DNA Technologies (Coralville, IA). All primers used in
the study are detailed in the supplementary material [48]. Primer
details are given in Table S2.
2.11. Western blot analysis
The total protein was isolated from myeloid cells by a protein lysis
buffer (50 mM TriseHCl, pH 7.5, 250 mM NaCl, 5 mM EDTA, 50 mM
NaF, and 0.5% Nonidet P-40; containing a protease inhibitor cocktail;
Sigma, St Louis, MO), as described before [48] and quantiﬁed using
BCA (Bicinchononic Acid assay kit; Thermo Fisher, Rockford, IL). An
equal amount of protein was separated by 10e12% SDS polyacrylamide gel electrophoresis and transferred onto the polyvinylidene
diﬂuoride membrane and blocked with 5% skimmed milk. iNOS,
Arginase 1, STAT-3, pSTAT3 were purchased from BD Biosciences
(San Jose, CA). IL-1b and DLST were purchased from Cell Signaling
Technology (Danvers, MA). S100A9 and CSF-R were purchased from
Proteintech (Rosemont, IL, USA). The dilutions used for the antibodies
are summarized in Table S3.
2.12. Seahorse metabolic analysis

2.7. Myeloid-derived suppressor PCR array
A myeloid-derived suppressor PCR (Real-Time Primers, MMDSC-I, PA,
USA) array was performed after isolating total RNA from the
CD11bþGr1þ myeloid cells (BD-IMAG GR1þ) of naïve (no tumor) and
ID8 tumor-bearing mice. This library proﬁles 88 genes involved in
immunosuppression. The quantitative expression of the gene was
calculated from the cycle threshold (CT) value of each sample and was
normalized using the housekeeping genes by using online PCR
quantiﬁcation software provided by the manufacturer.
2.8. Glucose metabolism RT2 proﬁler PCR array analysis
The total RNA was isolated from the CD11bþGr1þ myeloid cells using
a Qiagen RNeasyÒ Mini Kit (Qiagen, Germantown, MD) according to
the manufacturer’s instructions. Single-strand cDNA was synthesized
from 1 mg of total RNA by reverse transcription reaction using a Qiagen
RT2 First Strand Kit (Qiagen, Germantown, MD) and subjected to the
Glucose metabolism array that proﬁles the expression of 84 genes
involved in glucose metabolism (RT2 proﬁler PCR array-PAMM-006Z,
Qiagen). The quantitative expression of the gene was calculated
from the cycle CT value of each sample. The samples were analyzed in
duplicate and were normalized using the housekeeping genes by using
RT2 PCR array data analysis software provided by the manufacturer.
The gene list is provided in Supplementary Table 6.
2.9. ELISA
The expression levels of IL-6, IL-1b, IL- 4, and IFN-g (Biolegend ELISA
kits, San Diego, CA) and GM-CSF, G-CSF, VEGF, and S-CSF (R&D
Biosystems ELISA kit, Minneapolis, MN) in ascites and cell culture
supernatants were evaluated in accordance with the manufacturers’
instructions, as described earlier [43].
2.10. Real-time PCR
The total RNA was extracted from myeloid cells using an RNA assay kit
(Qiagen, Germantown, MD) and quantiﬁed by Qubit Fluorimeter
(Thermo Fisher Scientiﬁc, USA). The cDNA was synthesized as above.
RT-PCR reactions were performed in a 25 ml mixture (1 ml cDNA,
1  SYBR green buffer, forward and reverse speciﬁed primers) using
CFX BioRad Real-time PCR Detection System. Ribosomal protein L27
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2.12.1. Metabolic phenotype
CD11bþGr1þ myeloid cells were isolated from naïve and ID8 tumorbearing mice and were plated at the density of 3  105 cells/well in
Cell-Tak coated XFe 96 cell plates. The oxidative phosphorylation (OCR)
and extracellular acidiﬁcation (ECAR) rates were measured using an
XFe 96 seahorse analyzer (Agilent Seahorse XFe96 Analyzers), as
described earlier [48]. For measuring OCR, cells were incubated in an
XF base medium supplemented with 2 mmol/L glutamine, 10 mmol/L
glucose, and 1 mmol/L pyruvate. Various metabolic inhibitors were
injected to observe the effect of the oxidative phosphorylation and
extracellular acidiﬁcation rate. OCR measurements were recorded with
port injections of (1) oligomycin (1 mmol), (2) FCCP (0.5 mmol), and a
combination of (3) rotenone-antimycin at 1 mmol. ECAR, an indicator of
aerobic glycolysis, was measured by incubating cells in an XFe base
medium supplemented with 2 mmol/L glutamine. ECAR measurements were recorded after injecting with (1) glucose (10 mM), followed
by (2) oligomycin (2 mM), and (3) 2-DG (100 mM).
2.12.2. Mito Fuel Flex test
Mitochondrial fuel dependency and the capacity of CD11bþGr1þ cells
was estimated using a Seahorse XF Mito Fuel Flex test kit (Agilent,
USA). Dependency (cells relying on the particular pathway to meet its
baseline respiration) and capacity (cells depending on other pathways
when the depending pathway is inhibited) were measured for the use
of glucose, glutamine, and fatty acid as fuel. BM-derived myeloid cells
from naive and tumor-bearing mice were subjected to the fuel test to
measure OCR in the presence or absence of carnitine palmityl transferase 1A inhibitor etomoxir (4 mm) to inhibit fatty acid oxidation (FAO)
or glutaminase inhibitor BPTES (3 mm) to inhibit glutamine utilization or
UK5099 (2 mm) for inhibition of glycolysis. This test determines the
cellular dependence of the live cells on the metabolites to fuel their
mitochondrial metabolism and capacity for utilizing that substrate
when others were blocked. Capacity and dependence were calculated
as shown, according to the manufacturer’s instructions.
Capacity% ¼ 1 



ðBaseline OCR  Other 2 inhibitors OCRÞ
*100%
ðBaseline OCR  All other inhibitorsÞ

MOLECULAR METABOLISM 53 (2021) 101272 Ó 2021 The Author(s). Published by Elsevier GmbH. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
www.molecularmetabolism.com

Figure 1: Depletion of CD11bDGr1D myeloid cells by anti-Gr1 monoclonal antibody inhibits EOC progression. ID8-luc2 cells were injected intraperitoneally into C57Bl/6
mice. After 10 days of tumor initiation, mice were treated with IgG2b or anti-Gr1 mAb as described in methods. (A) Representative ﬂow cytometry plots and graph from n ¼ 3, of
total CD11bþGr1þ myeloid cells in the peripheral blood of mice treated with IgG2b mAb (left) or anti-Gr1 mAb (right). Numbers represent the frequency of cells in the indicated
gate. (Bi) Flow cytometry plots (n ¼ 3) representing LY6C and LY6G population from CD45þCD11bþ cells in mice treated with IgG2b mAb or anti-Gr1 mAb. (Bii) Flow cytometry
plots showing only the populations of interest after removing all negative populations for clarity of the gates. (Biii) Bar graphs represent the average percentage of cells in each
population. (C) KaplaneMeier graphs indicating overall survival (n ¼ 12) in ID8-luc2 mice untreated (control) or treated with IgG2b mAb or anti-Gr1 mAb; p ¼ 0.0385 by GehanBreslow-Wilcox test and p ¼ 0.0177 by ManteleCox test. (D) Average radiance (n ¼ 6) of bioluminescence signal of tumor progression of mice treated with IgG2b mAb or anti-GR1
mAb. The weeks represent post-tumor inoculation time points. (E) Dot plots (n ¼ 6) of mouse weight, abdominal circumference, and ascites volume of ID8-luc2 mice treated with
IgG2b mAb or anti-Gr1 mAb. (F) Representative H & E images of tumor tissue in ID8-luc2 mice treated with IgG2b mAb or anti-Gr1 mAb at 4x. (G) Representative images of Ki67
staining at 40 magniﬁcation. Tumor sections from all 6 mice/group were examineddrepresentative bar graph for Ki-67 proliferation index. (H) Representative ﬂow plots and bar
graphs for CD4þ and CD8þ T cell population in ID8-luc2 mice treated with IgG2b mAb or anti-Gr1 mAb. All analyses were carried out in mice after 5e6 weeks of tumor inoculation.
*p < 0.05, **p < 0.01, ***p < 0.001 anti-Gr1 mAb-treated mice compared to control IgG2b-treated mice as assessed by unpaired T-test.



ðBaseline OCR  Target 2 inhibitor OCRÞ
*100%
Dependenceð%Þ ¼ 1
ðBaseline OCR  All other inhibitors OCRÞ

2.13. Histological analysis
Tumor tissue was ﬁxed in 10% formaldehyde for 48 h and parafﬁnembedded. Sections were cut and processed for hematoxylin and
eosin (H&E) staining and immunohistochemistry to detect Ki-67, CD4,
CD8, and cleaved caspase 3. The Ki-67 antibody was purchased from
Abcam (Cambridge, MA) and used at a concentration of 1:200. Antibodies against CD4, CD8, and cleaved caspase 3 were obtained

from Cell Signaling Technology (Denver, MA), and all were used at a
1:100 dilution. Solutions obtained from Dako Cytomation (Carpinteria,
CA) were used for performing immunostaining, using the Dako
Autostainer Link 48, as described previously. A minimum of 3e6
slides per group and 6e10 ﬁelds per slide were evaluated under a
high-power ﬁeld, and the quantiﬁcation of stain intensity was performed by blinded pathologists (RA-F and EA) [42].
2.14. Statistical analysis
An unpaired t-test or one-way ANOVA was used where appropriate.
A Kaplan Meier analysis was used to determine the survival curve.
The signiﬁcance of survival curves was estimated by using the
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Figure 2: Depletion of CD11bDGr1D myeloid cells enhances PD1 immunotherapy. ID8-luc2 cells were injected intraperitoneally into C57Bl/6 mice. After 10 days of tumor
initiation, mice were treated with IgG2b or anti-Gr1 mAb or anti-PD1 mAb or a combination of both as described in methods. (A) KaplaneMeier graphs indicating overall survival
(n ¼ 12) under various treatments; p ¼ 0.0094 by Gehan-Breslow-Wilcox test and p ¼ 0.0042 by ManteleCox test on comparing PD1 alone to combination treatment; p ¼ 0.0011
by Gehan-Breslow-Wilcox test and p ¼ 0.0004 by ManteleCox test on comparing Gr1 alone to combination treatment. (B) Average radiance (n ¼ 6) of bioluminescence signal of
tumor progression of mice treated with various treatments. Weeks indicate post-tumor injection time points. Dot plots (n ¼ 6) of mouse weight (C), abdominal circumference (D),
and ascites volume (E) of ID8-luc2 mice treated with indicated treatments. (F) Representative images of Ki67 staining for assessing tumor cell proliferation. Images are shown at
4 magniﬁcation. Tumor sections from all 8 mice/group were examined. Ki-67 proliferation index is plotted as a bar graph (H). (G) Representative images of cleaved caspase 3
staining for assessing tumor cell apoptosis. Images are shown at 20 magniﬁcation. Tumor sections from 3 to 4 mice/group were examined. Positive cells were counted from a
minimum of 6 ﬁelds at HPF from each slide and quantiﬁed (I). (J) Bar graph representing the percent of CD11bþGr1þ myeloid cells in the ascites of mice under various treatments
(n ¼ 3). Bar graphs for CD4þ (K) and CD8þ (L) T cell population in ID8-luc2 mice with various treatments. *p < 0.05, **p < 0.01, ***p < 0.001 compared to IgG2b; #p < 0.05,
##
p < 0.01, ###p < 0.001 compared to anti-Gr1 and &p < 0.05, &&&p < 0.001compared to anti-PD1 as assessed by unpaired T-test.
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Gehan BresloweWilcox test and the ManteleCox tests. All analyses
were carried out using Prism 8 (GraphPad Software, La Jolla, CA).
3. RESULTS
3.1. Depletion of CD11b þ Gr1þ myeloid cells impedes the
progression of ovarian tumors and enhances antitumor immune
response
Immunosuppressive CD11bþGr1þ immature myeloid cells, also
identiﬁed as MDSCs, have been shown to accumulate in ovarian
cancer patients and the ID8 syngeneic model, and the depletion of
these cells has previously been demonstrated to suppress the progression of the ID8 tumors [24,49]. Using ID8-luc2 induced tumors, we
conﬁrmed that depleting CD11bþGr1þ myeloid cells by anti-Gr1 mAb
treatment depleted ~50% of CD11bþGr1þ myeloid cells in peripheral
blood compared to mice treated with an IgG2b mAb isotype at 6 weeks
post-tumor injections (Figure 1A). A signiﬁcant depletion in both PMNmyeloid cells (CD11b þ Ly6GhiLy6Clo) and M-myeloid cells
(CD11bþLy6GLy6Chi) was observed (Figure 1B). Survival analysis
revealed a signiﬁcant increase in the median survival of anti-Gr1 mAb
treated mice (median survival 61.5 days) compared to the IgG2b mAb
isotype (median survival 44.5 days) or control (median survival 46.5
days) groups (Figure 1C). Decreased bioluminescence signals after
anti-Gr1 mAb treatment suggested tumor growth was signiﬁcantly
suppressed compared to mice treated with the isotype control mAb
(Figure 1D). Furthermore, 6 weeks after tumor inoculation, mice that
received the anti-Gr1 mAb had reduced weight, a smaller abdominal
circumference, and a decreased ascites volume (Figure 1E). Histological analysis revealed that anti-Gr1 mAb treated mice had smaller
tumors than isotype-treated mice, as determined by H&E staining
(Figure 1F). Anti-Gr1 mAb treated mice also had a signiﬁcant reduction
in the number of proliferating cells compared to isotype-treated mice,
as determined by the Ki-67 index (Figure 1G). CD11bþGr1þ depletion
led to a signiﬁcant increase in the percentage of CD4þ and CD8þ T
cells in the ascites of anti-Gr1mAb-treated mice relative to IgG2btreated controls (3.5% vs. 0.5% and 1.8% vs. 0.6%, respectively;
Figure 1H).
As an alternative treatment approach, we used a pyrimidine analog,
gemcitabine, which has been reported to selectively eliminate suppressive myeloid cells without affecting other immune cells [50,51].
Similar to anti-Gr1 mAb treatment, the total number of CD11bþGr1þ
myeloid cells in the peripheral blood was reduced by approximately
50% after 6 weeks post-tumor inoculation in gemcitabine-treated mice
(Fig. S1A). Survival analysis revealed a signiﬁcant increase in the
median survival of gemcitabine treated (79 days) mice compared to
control mice (49 days; Fig. S1B). Gemcitabine treatment signiﬁcantly
reduced tumor growth, as evident from the quantiﬁcation of bioluminescence signal after 4 weeks of treatment (Fig. S1C). Gemcitabine
treatment also reduced body weight, abdominal circumferences, and
ascites volume assessed after 6 weeks post-tumor inoculation
(Fig. S1D). The decreased tumor burden in gemcitabine-treated mice
was further supported by smaller tumors seen by H&E staining
(Fig. S1E) and a lower Ki-67 index (Fig. S1F), indicating gemcitabinetreated mice have a decrease in actively proliferating cancer cells.
Gemcitabine treatment also resulted in an increased percentage of
total CD4þ and CD8þ T cells in the ascites (Fig. S1G). It is known that
gemcitabine treatment induces cancer cell death, and its effect is
primarily on the tumor cells and possibly secondary on the suppressive
myeloid cells. However, these results further demonstrate the correlation between cancer cell growth and suppressive myeloid cell
accumulation. Thus, as observed by us and others, alleviating

immunosuppression by depleting immunosuppressive CD11bþGr1þ
cells reduces ID8-Luc2 induced ovarian tumors and restores the
antitumor immune response.
3.2. CD11bþGr1þ depletion enhances the efﬁcacy of PD1
immunotherapy
A blockade of PD-1 in mice with ovarian cancer has been shown to
reduce the tumor burden in combination treatments [49,52,53]. To
evaluate the impact of depleting CD11bþGr1þ on anti-PD-1 immunotherapy, we performed combination and single treatments of antiGr1 mAb and anti-PD1 mAb in mice with ID8-luc2-induced EOC.
The median overall survival was signiﬁcantly increased upon treatment
with the anti-Gr1 mAb (59.5 days) and upon the PD1-blockade (63
days) compared to IgG2b mAb treatment (44 days). The combined
treatment signiﬁcantly extended the survival of ID8 tumor-bearing
mice (83 days) compared to the treatment alone and control groups
(Figure 2A). Furthermore, mice that received the combination treatment had a lower bioluminescence signal each week after the start of
the treatment, indicating smaller tumors compared to that in mice in
other groups (Figure 2B). The enhanced effects of the combination
treatment were also observed with the decrease in mouse weights,
abdominal circumference, and ascites volume compared to single or
control treatment groups (Figure 2C, D, E). The combination treatment
also resulted in a lower Ki-67 index number 6 weeks after tumor
inoculation (Figure 2 F, H). Though anti-Gr1 and anti-PD1 mAb treatments alone resulted in signiﬁcant apoptosis of ID8 tumor cells, a
greater increase in apoptotic cells was observed in tumors from mice
that received the combination therapy, as evident from the enhanced
number of cleaved caspase-3 positive cells in these tumors compared
to mice from other groups. (Figure 2 G, I). Thus, targeting CD11bþGr1þ
augments the antitumor effect of the PD1 blockade and results in
increased tumor cell death.
Immune cell proﬁling of the ascites showed that CD11bþGr1þ cells
were signiﬁcantly reduced upon treatment with anti-Gr1 mAbs or PD1
mAbs (Figure 2J), with the reduction in the combination group being
signiﬁcantly greater than the other groups (Figure 2J). The decreased
frequency of CD11bþGr1þ was accompanied by an enhanced population of CD4þ and CD8þ T cells in the ascitic environment of the ID8luc2 tumors of single mAb treated groups that were further increased
in mice that received combination therapy (Figure 2K,L). Notably,
immunohistochemical analysis of tumor sections showed similar signiﬁcant differences in the number of CD4þ and CD8þ T cells that had
inﬁltrated the ID8 tumors (Figs. S2A and B). Thus, CD11bþGr1þ
depletion combined with immunotherapy can act as a coordinated
approach to improve the immune response against ovarian tumors.
3.3. Adoptive transfer of CD11bþ Gr1þ myeloid cells promotes
ovarian cancer progression
To conﬁrm the role of CD11bþGr1þ in promoting ovarian cancer, we
isolated CD11bþGr1þ and CD11bþGr1- cells from the BM of wild-type
C57/B6 congenic CD45.2 mice harboring ID8-luc2 cells and adoptively
transferred (AdT) them by IV injections into congenic CD45.1 mice that
had received ID8-luc2 cells two weeks prior to the transfer of cells. ID8
tumor-bearing recipients of CD11bþGr1þ AdT had signiﬁcantly
increased bodyweight, abdominal circumference, ascites volume, and
tumor burden at 2 weeks post-AdT compared to the control group of
mice injected with ID8-luc2 cells but did not receive AdT or mice that
received CD11bþGr1- cells. (Figure 3AeD). Increased tumor burden
was also conﬁrmed by larger tumor nodules present in the
CD11bþGr1þ AdT mice, as seen by H&E staining of tumor tissues
(Figure 3E) and an increased Ki-67 index, indicating faster proliferating
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Figure 3: Adoptive transfer of tumor primed CD11bDGr1D myeloid cells promotes progression of EOC. CD11bþGr1þ or CD11bþGr1- myeloid cells were adoptively
transferred (AdT) from ID8-luc2 tumor primed CD45.2 congenic mice into sets of ID8-luc2 tumor-bearing congenic CD45.1 mouse by IV. A control set of mice received sham
injections. Bar graphs showing (A) body weight, (B) Abdominal circumference, (C) Ascites volume, and (D) tumor burden measured by the average radiance of bioluminescence
signal (n ¼ 6). (E) Representative H &E staining (10x) of tumor tissue from control, CD11bþGr1þ or CD11bþGr1- AdT mice 4 week post AdT. (F) Representative Ki67 expression in
tumor sections from mice 4 weeks post-AdT and the calculated Ki-67 index. A total of 8 HPF were studied from 3 to 4 tumor sections/group. Representative ﬂow cytometry plots of
CD45.2þCD11bþGr1þ cells in tumors (G, H) and ascites (J, K) from CD45.1 mice with and without tumor. Tumor bar graphs represent the pooled tumor tissue of 3 mice. Ascites
bar graph are from n ¼ 3. Representative ﬂow cytometry plots of CD45.2þCD11bþGr1- cells in tumors (G, I) and ascites (J, L) from CD45.1 mice with and without tumor. Tumor
bar graphs represent the pooled tumor tissue of 3 mice. Ascites bar graph are from n ¼ 3. Representative ﬂow plots of CD8þ (M, N)and CD4þ T (M, P) cells inﬁltrated in tumor and
the intracellular IFNg positive cells from respective CD8 (M, O) and CD4 (M, Q) populations of tumor inﬁltrates. Tumor bar graphs represent the pooled tumor tissue of 3 mice.
*p < 0.05, **p < 0.01 compared to control as assessed by unpaired T-test.

tumor cells (Figure 3F). Flow cytometry analysis detected the donor
CD45.2 CD11bþGr1þ cells in the tumors and ascites of the CD45.1
recipient mice, and they were absent in the control mice that did not
receive AdT, as expected. Donor CD45.2 CD11bþGr1- cells were also
detected in the tumors and ascites of the CD45.1 recipient mice,
though at lower numbers (Figure 3G,I, J, L). This ﬁnding suggests that
intravenous AdT CD11bþGr1þ cells home to the tumor and TME.
Concomitant with increased CD11bþGr1þ cells, AdT mice had a
reduction in CD4þ T and CD8þ T cells in tumors (Figure 3M, N, P),
signifying immunosuppression. Additionally, CD4þ and CD8þ T cell
populations expressed reduced intracellular IFN-g, indicating
decreased effector function (Figure 3O, Q). Thus, the increased number
of CD11bþ Gr1þ myeloid cells was shown to enhance ovarian cancer
growth and is associated with decreased tumor-inﬁltrating T cells.
3.4. Ovarian cancer environment enhances the
immunosuppressive phenotype of CD11b þ Gr1þ myeloid cells
Tumors are known to produce cytokines and chemokines that recruit
and promote the differentiation of immature myeloid cells into cells
with immunosuppressive capability [54,55]. We observed increased
levels of pro-immunosuppressive myeloid cell factors [17,18,54],
including GM-CSF (increasing trend), G-CSF, VEGF, and S-CSF, in the
ascites collected from mice bearing ID8 -luc2 tumors at 6 weeks
(Figure 4AeD). Levels of stromal cell-derived factors, such as IL-6 and
IL-4, were signiﬁcantly increased (Figure 4E,F), while IL-1b and IFN-g
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were unchanged (Figure 4G,H). This ﬁnding suggests that ovarian
cancer cells and the TME produce pro-recruitment and proimmunosuppressive factors that regulate CD11bþGr1þ myeloid
cells. To conﬁrm that the tumor primed myeloid cells acquire immunosuppressive characteristics, BM-derived CD11bþGr1þ myeloid cells
from naïve mice and mice bearing ID8-Luc2 tumors for 2 weeks were
subjected to a Myeloid-Derived Suppressor Real-Time PCR array. We
observed a robust increase in the expression of 18 canonical
immunosuppression-related markers (Figure 4I, Fig. S3A, Table S4).
The most recognized [17,18] upregulated immunosuppressive
markers, such as iNOS, arginase1, STAT3, IL-1b, S100A9, and CSFR,
were validated by western blots (Figure 4J, Fig. S3B). BM cells were
isolated from naïve and differentiated myeloid cells (as described in the
methods section) in the absence or presence of ID8 CM to determine
whether ex vivo conditions can mimic a similar induction of the
immunosuppressive markers, and they were found to increase the
expression of the same canonical markers (Fig. S3C). Furthermore, the
BM-derived CD11bþGr1þ myeloid cells from ID8-Luc2 tumor-bearing
mice were more effective in suppressing the T cell proliferation, as
assessed by a co-culture of CD4 T cells and myeloid cells in a T cell
suppression assay, which showed decrease in proliferating T cells and
IFN-g production compared to cells from naïve mice (Figure 4 K, L,
Fig. S3D). These data indicate that ovarian cancer cells and TME
produce CD11bþGr1þ recruiting factors and can induce immunosuppressive factors and markers in vivo and ex vivo and are active
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Figure 4: EOC environment enhances the immunosuppressive phenotype of CD11bDGr1D myeloid cells. Levels of GM-CSF (A), G-CSF (B), VEGF (C), C-SCF (D), IL-6 (E), IL-4 (F), IL1b (G), and IFN-g (H) in the peritoneal wash or ascites from non-tumor (control, con) and ID8-luc2 tumor-bearing mice (ID8 tumor) were measured by ELISA (n ¼ 3) after 6 weeks of tumor
growth. (I) Total RNA was isolated from BM-derived CD11bþGr1þ myeloid cell control and ID8 tumor, and a mouse myeloid-derived suppressor PCR array was performed. Bar graph
represents the fold-change of gene expression in tumor primed vs. naïve myeloid cells. (J) Protein expression of iNOS, arginase 1, STAT 3, IL-1b, CSFR, and S100A9 in CD11bþGr1þ myeloid
cells isolated from control and ID8 tumor-bearing mice. Bar graphs represent the normalized density from 3 individual blots. (K) T cell suppression assay performed by co-culturing
CD11bþGr1þ myeloid cells from non-tumor and ID8 tumor-bearing mice with CFSE labeled CD4 cells isolated from naïve mice at 1:2 ratio (n ¼ 3). T cell proliferation was assayed by
ﬂow cytometry on day 5 by measuring the CFSE intensity individually in each generation. Data from generation P1eP3 is shown. (L) From the same cells, day 3 supernatant was collected, and
IFNg levels were measured by ELISA. *p < 0.05, **p < 0.01, ***p < 0.01 tumor compared to control as assessed by unpaired T-test. The expanded forms of abbreviations are detailed in the
Supplementary Table S4.
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Figure 5: EOC microenvironment induces an energetic metabolic state in CD11bDGr1D myeloid cells. CD11bþGr1þ were isolated from BMs of control (no tumor injection)
and mice with ID8-luc2 tumor at 2 weeks and subjected to Seahorse analysis and energy targeted metabolomics. (A) Oxygen consumption rate (OCR) was assessed in real-time
using an XFe Seahorse analyzer as described in methods. Port injections of (1) oligomycin, (2) FCCP, and a combination of (3) rotenone-antimycin were given. (B) The bar graph
represents basal and stressed OCR (n ¼ 3). (C) Extracellular acidiﬁcation rate (ECAR) was measured with port injections of (1) glucose, (2) oligomycin, and (3) 2-DG. (D) The bar
graph represents basal and stressed ECAR (n ¼ 3). (E) A quadrant plot indicates the metabolic shift of energy phenotype at basal and stressed levels. (F) MetaboAnalyst analysis
showing the most signiﬁcant and impacted pathways in the CD11bþGr1þ isolated from ID8 tumor mice compared to non-tumor mice. (G) Bar graphs showing the metabolite levels
that changed signiﬁcantly, as quantiﬁed by metabolomics in CD11bþGr1þ cells isolated from control and tumor mice. *p < 0.05, **p < 0.01, ***p < 0.01 tumor compared to
control as assessed by unpaired T-test.

participants in maintaining a myeloid cell-driven immune-suppressive
environment.
3.5. Ovarian cancer microenvironment induces an energetic
metabolic state in CD11bþ Gr1þ myeloid cells
Recent research suggests that the activity of immune cells is deﬁned
and modulated by the energy metabolism dictated by the TME [56,57].
To assess whether the ovarian TME could modulate the energy
metabolism of the CD11bþGr1þmyeloid cells, BM-derived cells from
naïve mice and mice bearing ID8-Luc2 tumors for 2 weeks were
analyzed by a Seahorse XFe96 analyzer in real-time (to deﬁne their
metabolic proﬁle. The tumor-primed CD11bþGr1þ myeloid cells
showed an increased basal and stressed OCR, indicating increased
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mitochondrial respiration compared to naïve myeloid cells
(Figure 5A,B). No signiﬁcant change was seen in the ECAR at the
baseline or stressed conditions, suggesting no glycolysis change under
tumor conditions in the myeloid cells (Figure 5C,D). The resulting
energy phenotype indicated a basal aerobic energy phenotype in the
tumor-primed myeloid cells that further moved to an energetic
phenotype when stressed (Figure 5E).
Conversely, naïve myeloid cells showed a basal glycolytic phenotype
that increased under stressed conditions (Figure 5E). To examine
whether similar metabolic changes can be mimicked exvivo, BM cells
were analyzed for energy phenotypes when differentiated in the
absence or presence of ID8 CM. In the presence of ID8 CM, an
increased OCR at the baseline and stressed conditions (Figs. S4A and
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B) were observed, similar to the in vivo conditions. Interestingly, the
ID8 CM also increased ECAR, probably due to the direct and profound
exposure to TME (Fig. S4 C, D). Like tumor priming, ID8 CM also
conferred a basal aerobic energy phenotype that increased to an energetic phenotype under stressed conditions (Fig. S4E). Thus, both
in vivo tumor presence and ex vivo exposure to the ovarian TME can
modulate the metabolic phenotype of CD11bþGr1þ myeloid cells.
To further conﬁrm that mitochondrial respiration is affected, we performed an LC-MS/MS-based targeted metabolomics analysis for the
quantitative proﬁling of ~250 energy pathway metabolites [46,47].
Unsupervised PCA showed that myeloid cells from naïve and tumorbearing mice could be separated based on their metabolic differences (Fig. S4F). Pathway analysis by MetaboAnalyst 4.0, which uses
high-quality KEGG pathways as a knowledge base, revealed 25
pathways with signiﬁcance (Table S5) and impact value. Most of these
pathways were related to mitochondrial respiration pathways. Nicotinate and nicotinamide metabolism and the TCA cycle were identiﬁed
to be the two pathways with high signiﬁcance and impact (Figure 5F,
Fig. S4G). Nicotinate and nicotinamide are essential for various cellular
and metabolic processes, including energy metabolism and the TCA
cycle [58]. Charting the individual metabolite levels showed a signiﬁcant increase in the metabolites of the TCA and associated pathways,
including citrate, malate, itaconate, glutamic acid, and arginine. Pyruvate levels showed an increasing trend while lactate levels were
decreased, suggesting the incorporation of lactate into pyruvate and its
feeding into the TCA cycle (Figure 5G). Thus, ovarian tumor-primed
myeloid cells undergo metabolic reprogramming toward applying
increased mitochondrial respiration for their immunosuppressive
function.

(Figure 6P). Together, these data strongly suggest that glutamine is an
essential mitochondrial respiration fuel for the CD11bþGr1þ myeloid
cells under the inﬂuence of ovarian tumors, and its TME and targeting
glutamine metabolism in myeloid cells may inhibit their immunosuppressive ability.

3.6. Enhanced metabolic state and immunosuppressive function of
CD11bþ Gr1þ myeloid cells are fueled by the glutamine energy
pathway
We sought to determine which mitochondrial fuel energy pathway is
primarily responsible for the increased mitochondrial respiration and the
increased immunosuppressive function of the myeloid cells. BM-derived
CD11bþGr1þ cells from naïve mice and mice bearing ID8-Luc2 tumors
for 2 weeks were subjected to the Mito Fuel Flex assay, as described in
the methods section. We observed that myeloid cells from tumorbearing mice were highly dependent on glutamine for meeting their
metabolic needs and showed an increased capacity to use glucose in the
absence of glutamine (Figures 6A and Fig. 5SA, B). To validate this
ﬁnding, we measured the effect of the three fuel pathway inhibitors
individually on OCR and ECAR proﬁles in differentiated BM-MDSCs in the
absence or presence of ID8 CM. We found that glutaminolysis inhibition
by BPTES signiﬁcantly inhibited OCR (Figure 6 B, D) without affecting
ECAR (Figure 6C, E), resulting in a basal quiescent metabolic phenotype
that moved to the glycolytic phenotype under stressed conditions
(Figure 6 F). Glycolysis inhibition by 2-DG resulted in increased OCR and
decreased ECAR, as expected, explaining the basal aerobic metabolic
phenotype, which moved to an energetic phenotype under stressed
conditions (Figure 6D,E, F). The inhibition of FAO by etomoxir had no
signiﬁcant effect on either pathway. Another glutamine antagonist, DON,
also signiﬁcantly inhibited OCR and ECAR and moved the metabolic
phenotype from quiescent under basal conditions to glycolytic under
stressed conditions (Figure 6GeK). As further conﬁrmation, we also
observed that glutamine deprivation (low glutamine conditions) inhibited
mitochondrial respiration (Figure 6 L, M), similar to glutamine pathway
inhibitors. However, not much effect on ECAR was observed (Figure 6 N,
O). Like the inhibitors, the metabolic phenotypes were quiescent at basal
and glycolytic at stressed conditions in the absence of glutamine

3.8. Increased metabolic activity and function of myeloid cells is
due to the increased expression of dihydrolipoamide succinyl
transferase, a subunit of the alpha-ketoglutarate dehydrogenase
complex
To identify a speciﬁc factor playing the pivotal role in the increased
glutamine metabolism of CD11bþGr1þ myeloid cells, we examined the
expression of 84 genes involved in 5 different metabolic pathways
(glycolysis, TCA cycle, pentose phosphate pathway, gluconeogenesis,
and glycogenolysis) using the glucose metabolism PCR array in
CD11bþGr1þ myeloid cells isolated from naïve mice and mice bearing
ID8-Luc2 tumors for 2 weeks. Tumor-primed CD11bþGr1þ myeloid
cells showed a signiﬁcant increase in most genes involved in the TCA
cycle and glycolysis (Figure 8 and Fig. S7 A, Table S6), with dihydrolipoamide succinyl transferase (DLST), mitochondrial enzyme and a
subunit of the a-KGDC in TCA cycle [59], increasing more than 100fold (Figure 8A, Fig. S7 A, B). Key TCA cycle upregulated genes
were also validated under conditions of glutamine deprivation and
were found to be signiﬁcantly decreased (Fig. S7C), including DLST
(Figure 8D). The increase in DLST was validated again at the protein
and RNA level in the tumor-primed CD11bþGr1þ myeloid cells isolated
from mouse BM (Figure 8B). In addition, ID8 CM was also able to
induce the robust expression of DLST in CD11bþGr1þ myeloid cells
(Fig. S7C), indicating the importance of ovarian TME in modulating the
metabolism of myeloid cells. To examine whether the increased DLST
expression was due to increased glutamine availability to the myeloid
cells, the BM-derived cells were treated with BPTES or subjected to
low glutamine in the presence of ID8 CM. Puriﬁed CD11bþGr1þ
myeloid cells treated with BPTES showed decreased DLST expression
at the protein and mRNA level (Figure 8C). However, 2-DG treatments
did not have any effect, indicating the speciﬁcity of glutamine availability as the primary determinant of DLST expression.

3.7. Targeting glutamine metabolism inhibits the
immunosuppressive function of CD11bþ Gr1þ myeloid cells
To analyze the contribution of glutamine metabolism, we tested if
targeting glutamine metabolism will inhibit the immunosuppressive
marker’s expression and function. Inhibition of glutaminolysis by
BPTES signiﬁcantly inhibited the expression of immunosuppressive
markers including STAT 3, VEGF, iNOS, and arginase 1; (Figure 7AeD),
decreased the secretory immunosuppressive markers including IL-6,
IL-1b, NO, GM-CSF, and G-CSF; (Figure 7EeI) and inhibited the protein expression of iNOS, STAT 3, and arginase 1, whereas the IL-1b
protein level was unaffected (Figure 7J). Furthermore, BM-derived
CD11bþGr1þ myeloid cells treated with BPTES were less efﬁcient in
inhibiting T cell proliferation and IFNg production than ID8 CM exposed
cells alone (Figure 7 K, L). As a complementary approach, glutamine
deprivation also decreased immunosuppressive marker expressions,
such as iNOS, STAT 3, and arginase 1, at the protein level (Fig. S6A)
and decreased STAT 3, VEGF, iNOS, arginase 1, IL-6, and CSF at the
mRNA level (Figure 6BeG). Myeloid cells pre-exposed to low glutamine
were less effective in causing T cell suppression and inhibiting IFN-g
(Fig. S6 H, I) than the cells in regular glutamine media. These data
show that inhibiting glutamine utilization by pharmacological inhibitors
or glutamine deprivation decreased the immunosuppressive function
of ovarian TME-primed CD11bþGr1þ myeloid cells.
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Figure 6: The glutamine energy pathway fuels enhanced metabolic state and immunosuppressive function of CD11bDGr1D myeloid cells. CD11bþGr1þ were isolated from
BMs of control (no tumor), and mice injected with ID8-luc2 tumor at 2 weeks were subjected to (A) Mito Fuel Flex assay to assess dependency and capacity after blocking the different
energy pathways using speciﬁc inhibitors UK5009 (glucose inhibitor), BPTES (glutamine inhibitor) and etomoxir (fatty acid oxidation inhibitor). (B) OCR was assessed in real-time using
XFe Seahorse analyzer as described in methods, in CD11bþGr1þ myeloid cells differentiated from BM by exposure of GM-CSF/IL-6 and ID8 conditioned media (CM) in the absence or
presence of metabolic inhibitors of 2-DG (glycolysis inhibitor), BPTES (glutaminase inhibitor) and etomoxir (fatty acid oxidation inhibitor). Port injections were given as described before.
(D) The bar graph represents basal and stressed OCR (n ¼ 3). (C) Measurement of ECAR proﬁle as described before. (E) The bar graph represents basal and stressed ECAR (n ¼ 3). (F)
Energy phenotype shifts under the presence of various metabolic inhibitors. BM-derived CD11bþGr1þ myeloid cells were treated with glutaminase inhibitor DON, and OCR (G, H) and
ECAR (I, J) were assessed similarly (n ¼ 3). (K) Energy phenotype shifts under the presence of glutaminase inhibitor DON. (LeP) Similar metabolic analysis under regular glutamine
(2 mm) and low glutamine (0.5 mm). *p < 0.05, **p < 0.01, and ***p < 0.001, treatments compared to CM as assessed by unpaired T-test.
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Figure 7: Targeting glutamine metabolism inhibits the suppressive function of CD11bDGr1D myeloid cells. CD11bþGr1þ myeloid cells isolated from the BM and exposed
to ID8 conditioned media (CM) were treated with BPTES (10 mmol/L) for 48 h. (AeD) RT-PCR mRNA expression of STAT-3, VEGF, iNOS, and arginase (n ¼ 3). (EeI) Cell culture
supernatants from the same cells were collected, and levels of IL-6, IL-1b, GM-CSF, and G-CSF were measured by ELISA. NO levels were (G) measured by Griess reagent (n ¼ 3).
(J) Protein expression of iNOS, STAT 3, arginase 1, and IL-1b was measured by immunoblotting. Bar graphs represent the normalized density from 3 independent blots. (K) The
immunosuppressive function of myeloid cells was tested by their ability to suppress T-cell proliferation as before and (L) IFNg production in the absence or presence of BPTES
(n ¼ 3). *p < 0.05, **p < 0.01, and ***p < 0.001, BPTES treatment compared to CM as assessed by unpaired T-test.

Similarly, glutamine deprivation also inhibited DLST expression at
protein and RNA levels (Figure 8D). Next, we employed a novel a-KGDC
inhibitor, MOV [60], which inhibited DLST expression and the
expression of immunosuppressive markers, including iNOS, arginase
1, and pSTAT3 (Figure 8E,F). To test whether inhibition of DLST can
alter the metabolic phenotype of myeloid cells, we performed a Seahorse analysis in the absence or presence of the DLST (a-KGDC) inhibitor. MOV treatment reduced the basal OCR but did not affect the
stressed OCR levels (Figure 8G,H). MOV’s inability to inhibit stressed
OCR may be due to the inhibitory mechanism of MOV, which the

mitochondria can overcome during the metabolic stress conditions.
Basal and stressed ECAR levels decreased in the MOV-treated myeloid
cells (Figure 8I,J). MOV-treated myeloid cells also showed a decreased
ability to suppress T cell proliferation and increase in IFN-g production
compared to the control ID8 CM group (Figure 8 K, L). Together, these
data suggest that targeting glutamine metabolism through DLST (a2KGDC) inhibition may be a novel approach in inhibiting the immunosuppressive function of CD11bþGr1þ myeloid cells in the ovarian
TME, leading toalleviation of immunosuppression and decreased
ovarian tumor growth.

MOLECULAR METABOLISM 53 (2021) 101272 Ó 2021 The Author(s). Published by Elsevier GmbH. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
www.molecularmetabolism.com

13

Original Article

Figure 8: Increased metabolic activity and function of myeloid cells are dependent on the increased expression of DLST. CD11b þ Gr1þ myeloid cells were isolated from
BMs of control (no tumor), and mice injected with ID8-luc2 tumors at 2 weeks were subjected to (A) Glucose metabolism PCR array. The bar graph shows 2-fold and higher
upregulated genes in the CD11bþGr1þ cells from tumor-bearing mice (B) immunoblotting and RT-PCR in CD11bþGr1þ myeloid cells from control and ID8 mice. (C) Differentiated
BM-derived CD11bþGr1þ myeloid cells exposed to ID8 CM were treated with 2DG or BPTES, and DLST expression was examined by immunoblotting and RT-PCR. (D) Differentiated
BM-derived CD11bþGr1þ myeloid cells exposed to ID8 CM were subjected to low or normal glutamine levels, and DLST expression was examined by immunoblotting and RT-PCR.
(E) Differentiated BM-derived CD11bþGr1þ myeloid cells exposed to ID8 CM were treated with DLST inhibitor, MOV at 1-, 10-, and 20 mM concentrations for 48 h, and
immunoblotting was performed to measure DLST, iNOS, arginase 1, pSTAT3, and total STAT-3 expression. (F) Bar graphs represent the normalized density of the western blots from
3 individual blots. (G, H) OCR proﬁle of differentiated BM-derived CD11bþGr1þ myeloid cells exposed to ID8 CM in the presence or absence of MOV. (I, J) ECAR proﬁle of
differentiated BM-derived CD11bþGr1þ myeloid cells exposed to ID8 CM in the presence or absence of MOV. (K) CD11bþGr1þ myeloid cells treated with DLST inhibitor were cocultured with CD4þ T cells in 1:2 and 1:4 ratio to analyze T-cell proliferation (L) IFNg levels by ELISA in the supernatant on day 3. **p < 0.01, ***p < 0.001, ****p < 0.0001
treatments compared to control of CM as assessed by unpaired T-test.
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4. DISCUSSION
In this study, we elucidate the critical role of ovarian cancer cells and
their microenvironment in promoting the immunosuppressive ability of
CD11bþGr1þ myeloid cells and creating an immunosuppressive
environment that promotes its development. As shown by others
[16,25,49], we validated that CD11bþGr1þ myeloid cells encouraged
EOC growth, and depleting CD11bþGr1þ myeloid cells reduced EOC
growth, rescued the immune decline, and enhanced immunotherapy
(Figures 1e3), suggesting that targeting CD11bþGr1þ may be an
effective treatment approach alone or in combination. The detrimental
role of immunosuppressive CD11bþGr1þ myeloid cells (also referred
to as MDSCs) has been well-established in various other cancer types
[61,62].
Since their initial description as vascular leukocytes with an immunosuppressive ability [63e65], there has been a growing understanding of the contributions of the immunosuppressive ability of
CD11bþGr1þ myeloid cells and the complex immunometabolism
mechanisms regulating their function. The chemoattractants that recruit the immature myeloid cells are well documented and produced by
both the tumor cells and the cells of the microenvironment [17,66]. In
EOC, the role of IL-6, 1L-10, prostaglandin E2, stromal-derived factor1, GM-CSF, G-CSF, IL-4, VEGF, COX2, IFN-g, TNF-a, and oxidative
stress has been shown to aid the recruitment of immunosuppressive
CD11bþGr1þ myeloid cells [55]. In accordance, we found that ovarian
TME had increased levels of GM-CSF, G-CSF, VEGF, IL-6, and IL-4
(Figure 4). Not only did the ovarian TME produce recruitment factors,
but it also induced various immunosuppressive markers, including
canonical markers, such as STAT 3, iNOS, arginase 1, S100A9, CSFR,
and IL-1b. In addition, the increased immunosuppressive marker
expression translated to increased immunosuppression, as seen by T
cell proliferation assays (Figure 4), the primary immunosuppressive
function of CD11bþGr1þ myeloid cells [17,67].
Recently, immunometabolism, whereby immune cell development and
function are regulated by their distinct energy metabolism probably
cued by the microenvironment, is becoming well-accepted [33,57]. In
addition, the dysregulated cancer cell metabolism has been shown to
affect the metabolism of immune cells and their function [68].
CD11bþGr1þ myeloid cells have also been recently shown to rely on
energy metabolism pathways for their growth and immunosuppressive
function [39]. We also observed that the ovarian TME modulates the
energy metabolism of CD11bþGr1þ myeloid cells. The tumor-primed
in vivo isolated myeloid cells and the ex vivo generated ID8 CM
stimulated myeloid cells had enhanced oxidative phosphorylation
(OXPHOS) compared to myeloid cells that were not exposed to any
tumor stimulus at functional and metabolite levels (Figure 5). The Mito
Fuel Flex test revealed that the increased OXPHOS is fueled by and is
dependent on glutamine (Figure 6), which was corroborated by
increased TCA metabolites, including those associated with glutamine
metabolism (i.e., glutamic acid and arginine, Figure 5G). We established glutamine as the fuel for increased OXPHOS by showing that
only the inhibition of glutaminolysis (and not glycolysis or FAO) can
inhibit OXPHOS at both basal and stressed conditions, which was
further strengthened by the use of another pharmacological glutaminolysis inhibitor, DON, and glutamine deprivation (Figure 6).
Furthermore, the inhibition of glutamine metabolism resulted in a
reduction of immunosuppressive markers and the function of
CD11bþGr1þ myeloid cells (Figure 7). These data strongly suggest
that glutamine dependency is central for increasing the metabolic
capacity of myeloid cells that translates to increased immunosuppressive ability. Recent studies have reported that targeting glutamine

metabolism in many types of cancers, enhanced tumor-speciﬁc immunity by changing the function of myeloid cells [35,40,44]. The
metabolic regulation by energy pathways in regulating MDSC development and function has been recently investigated. Most of the reports studying the metabolic regulation of CD11bþGr1þ myeloid cells
have investigated how the altered metabolism of cancer cells changes
the metabolic activity and function of immunosuppressive
CD11bþGr1þ myeloid cells (referred to as MDSCs in most
publications).
Li et al. demonstrated that increased glycolysis in the 4T1 breast
cancer model and patient samples regulate the expression of G-CSF
and GM-CSF required for MDSC development and immune evasion
[35]. Jian et al. showed that MDSCs from the 4T1 breast cancer mouse
model exhibit increased levels of glycolysis metabolites essential for
MDSC expansion and survival via the prevention of excess reactive
oxygen species [36]. Using lung tumor and lymphoma mouse models,
mTOR-induced glycolysis was shown to be a driver of M-MDSC
expansion and immunosuppressive properties [37,38]. However, the
last three studies did not examine functional energy metabolism to
assess whether both glycolysis and/or OXPHOS were also increased.
Though we observed an increase in the glycolytic enzyme expression
in the targeted array studies, the glycolysis inhibitor 2-DG showed a
minimal effect on OXPHOS in the immunosuppressive CD11bþGr1þ
myeloid cells in our system (Figure 6). A more recent study demonstrated that M-MDSCs and TAMs present in renal carcinoma TME were
imbibing increased glucose compared to any other cells, also translating to increased glycolysis and mitochondrial respiration [69]. We
also found that the immunosuppressive CD11bþGr1þ myeloid cells did
exhibit a capacity to use glycolysis in the absence of glutamine
(Figure 6), suggesting that glycolysis may also play a role in maintaining the energy metabolism of myeloid cells. Lipid metabolic
pathways have also been implicated in regulating the immunosuppressive function of tumor-associated MDSCs. Well-designed studies
by the Ochoa group demonstrated that lipid uptake and accumulation
fostered by tumor cells resulted in increased OCR via increased FAO,
eventually leading to the increased immunosuppressive ability of
MDSCs associated with lung, colon, and thymoma tumor models
[34,70]. In our current study, the inhibition of FAO by etomoxir did not
affect OCR or Mito fuel dependency or capacity (Figure 6), which may
suggest a minor role of FAO in ovarian tumor-associated immunosuppressive CD11bþGr1þ myeloid cells.
Glutamine metabolism feeding into the TCA cycle and regulating the
function of immunosuppressive CD11bþGr1þ myeloid cells has
recently been reported in other tumor types. Wu et al. in a comprehensive study using patient-derived and 4T1 breast cancer preclinical
model identiﬁed glutaminolysis as the critical metabolic pathway
regulating the proliferation and activation of immature myeloid cells,
regardless of glucose availability [40]. They further showed that
restoration of the TCA cycle was due to increased a-ketoglutarate (aKG) derived from glutamine. Recently, Oh et al. showed that inhibition
of glutamine metabolism in 4T1 breast cancer and 3LL lung cancer
preclinical models resulted in immunogenic tumor cell death. Inhibition
of glutamine metabolism in myeloid cells led to apoptosis of MDSCs
and interestingly, converted suppressive MDSCs to a pro-inﬂammatory
anti-tumor phenotype [44].
Thus, these studies, along with ours, show the vital role of glutamine
metabolism in regulating the metabolism and function of immunosuppressive CD11bþGr1þ myeloid cells, ultimately affecting the immune environment of tumors and the antitumor immune response. The
glutamine pathway has been established as an upregulated metabolic
pathway in many cancers, including ovarian cancer, in which it
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supports the altered cancer cell metabolism and is crucial for nucleotide and amino acid biosynthesis, glutathione generation for maintaining redox and various other processes [71,72]. Our current study
does not distinguish whether the increased glutamine metabolism is
due to exogenous glutamine provided by the TME or the upregulation of
intrinsic glutamine metabolism of myeloid cells. Our array results and
effects of mitochondrial glutaminase inhibitors may suggest that the
immunosuppressive CD11bþGr1þ myeloid cells are able to potentiate
their intrinsic glutamine metabolism and fuel the TCA cycle.
To identify a speciﬁc target, we performed a metabolism gene
expression-based PCR array, which revealed DLST, a component of
aKGDC, increased by more than 100-fold in tumor-primed
CD11bþGr1þ myeloid cells. a-KGDC, an essential enzyme system of
the TCA cycle, is a metabolic hub that is a regulator of the signaling
metabolite a-KG and regulates cellular redox, and it is interconnected
with various metabolic pathways, including glutamine. Glutaminolysis
results in the synthesis of a-KG, which may be oxidized by mitochondrial a-KGDC pushing the TCA cycle or reduced and exported to
the cytosol and converted to acetyl CoA and aid fatty acid biosynthesis
[59]. The importance of a-KGDC in regulating various aspects of
cancer cells is well documented; however, the roles of individual
components have not been studied [59,73,74]. The a-KGDC comprises
of 3 enzyme components (E1-3) that work stepwise to generate
succinyl CoA from a-KG. DLST is the E2 enzyme that carries out the
reductive succinylation step in the formation of succinyl Co-A [59].
DLST is a non-redundant enzyme, and its deﬁciency leads to the
complete disruption of the TCA cycle [59]. Recently, it has been
suggested that DLST might be an essential gene in the etiology of
pheochromocytomas and paragangliomas, a type of rare, heritable
neuroendocrine tumor that carries mutations in various genes
encoding enzymes of the TCA cycle [75]. Anderson et al. showed that
DLST inactivation delayed Myc-induced leukemogenesis in a zebraﬁsh
model [76]. CPI-613, a DLST/a-KGDC non-speciﬁc inhibitor, is being
tested in more than 25 clinical trials combined with chemotherapy
drugs against various cancer types (ClinicalTrails.gov). In addition, it
may be worthwhile to examine whether EOC cells also express
increased DLST, as they are also reported to have a glutamine dependency [77].
To the best of our knowledge, this is the ﬁrst report to demonstrate a
connection between immunosuppressive CD11bþGr1þ myeloid cells
and DLST gene expression in EOC. To validate the relationship between
the glutamine pathway and DLST expression, we show that glutaminolysis antagonism and glutamine deprivation reduced DLST
expression, suggesting that glutamine availability regulates DLST.
DLST (a-KGDC) inhibition reduced the immunosuppressive marker
expression and OXPHOS and reversed the T cell suppression by
CD11bþGr1þ myeloid cells, suggesting a pivotal role for DLST in
regulating the tumor-induced immunosuppressive function of
CD11bþGr1þ myeloid cells.
Overall, our data describe the novel metabolic dependence of the
immunosuppressive function of CD11bþGr1þ myeloid cells mediated by
the ovarian TME. Additional work is needed to identify the source of
glutamine that fuels the CD11bþGr1þ myeloid cell metabolism and
corroborate the increased DLST expression in patient-derived myeloid
cells. This study provides evidence supporting the essential role of
glutaminolysis in myeloid cells and identiﬁes DLST as a speciﬁc novel
target in reducing the immunosuppressive effect of CD11bþGr1þ
myeloid cells and in potentially improving antitumor immunotherapy
approaches. Targeting DLST may have the dual beneﬁt of targeting the
glutamine pathway in tumor cells and immunosuppressive myeloid cells.

16

FUNDING
This work was supported by DOD W81XWH-16-OCRP awarded to RR and Patterson
Endowment funds awarded to AM. RR is supported by R01CA249188. MPU is
supported by Henry Ford Cancer Institute Post-doctoral Fellowship. SG is supported
by National Institutes of Health grants NS112727 and AI144004. The funding sources
had no role in study design, data collection, and interpretation, or the decision to
submit the work for publication.

CONFLICT OF INTEREST
None declared.

APPENDIX A. SUPPLEMENTARY DATA
Supplementary data to this article can be found online at https://doi.org/10.1016/j.
molmet.2021.101272.

REFERENCES
[1] Bogani, G., Lopez, S., Mantiero, M., Ducceschi, M., Bosio, S., Ruisi, S., et al.,
2020. Immunotherapy for platinum-resistant ovarian cancer. Gynecologic
Oncology 158(2):484e488.
[2] Coukos, G., Tanyi, J., Kandalaft, L.E., 2016. Opportunities in immunotherapy of
ovarian cancer. Annals of Oncology 27(Suppl 1):i11ei15.
[3] Liu, S., Matsuzaki, J., Wei, L., Tsuji, T., Battaglia, S., Hu, Q., et al., 2019.
Efﬁcient identiﬁcation of neoantigen-speciﬁc T-cell responses in advanced
human ovarian cancer. J Immunother Cancer 7(1):156.
[4] Odunsi, K., Jungbluth, A.A., Stockert, E., Qian, F., Gnjatic, S., Tammela, J.,
et al., 2003. NY-ESO-1 and LAGE-1 cancer-testis antigens are potential targets
for immunotherapy in epithelial ovarian cancer. Cancer Research 63(18):
6076e6083.
[5] Szender, J.B., Papanicolau-Sengos, A., Eng, K.H., Miliotto, A.J., Lugade, A.A.,
Gnjatic, S., et al., 2017. NY-ESO-1 expression predicts an aggressive
phenotype of ovarian cancer. Gynecologic Oncology 145(3):420e425.
[6] Cancer Genome Atlas Research, N., 2011. Integrated genomic analyses of
ovarian carcinoma. Nature 474(7353):609e615.
[7] Tothill, R.W., Tinker, A.V., George, J., Brown, R., Fox, S.B., Lade, S., et al.,
2008. Novel molecular subtypes of serous and endometrioid ovarian cancer
linked to clinical outcome. Clinical Cancer Research 14(16):5198e5208.
[8] Adams, S.F., Levine, D.A., Cadungog, M.G., Hammond, R., Facciabene, A.,
Olvera, N., et al., 2009. Intraepithelial T cells and tumor proliferation: impact
on the beneﬁt from surgical cytoreduction in advanced serous ovarian cancer.
Cancer 115(13):2891e2902.
[9] Azarianpour, S., Corredor, G., Bera, K., Leo, P., Braman, N., Fu, P., et al.,
2020. Computer extracted features related to the spatial arrangement of tumor-inﬁltrating lymphocytes predict overall survival in epithelial ovarian cancer
receiving adjuvant chemotherapy. In: Medical imaging 2020: digital pathology.
International Society for Optics and Photonics.
[10] Sato, E., Olson, S.H., Ahn, J., Bundy, B., Nishikawa, H., Qian, F., et al., 2005.
Intraepithelial CD8þ tumor-inﬁltrating lymphocytes and a high CD8þ/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer.
Proceedings of the National Academy of Sciences of the U S A 102(51):
18538e18543.
[11] Zhang, L., Conejo-Garcia, J.R., Kasaros, D., Gimotty, P.A., Massobrio, M.,
Regnani, G., et al., 2003. Intratumoral T cells, recurrence, and survival in
epithelial ovarian cancer. New England Journal of Medicine 348(3):203e213.
[12] Brahmer, J.R., Tykodi, S.S., Chow, L.Q.M., Hwu, W.-J., Topalian, S.L.,
Hwu, P., et al., 2012. Safety and activity of anti-PD-L1 antibody in patients

MOLECULAR METABOLISM 53 (2021) 101272 Ó 2021 The Author(s). Published by Elsevier GmbH. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
www.molecularmetabolism.com

[13]

[14]

[15]

[16]
[17]
[18]

[19]
[20]

[21]

[22]

[23]

[24]

[25]

[26]

[27]

[28]

[29]

[30]

with advanced cancer. New England Journal of Medicine 366(26):2455e
2465.
Disis, M.L., Patel, M.R., Pant, S., Infante, J.R., Lockhart, A.C., Kelly, K., et al.,
2015. Avelumab (MSB0010718C), an anti-PD-L1 antibody, in patients with
previously treated, recurrent or refractory ovarian cancer: a phase Ib, openlabel expansion trial [abstract]. Journal of Clinical Oncology 33(15 Suppl):
5509.
Hamanishi, J., Mandai, M., Ikeda, T., Minami, M., Kawaguchi, A.,
Murayama, T., et al., 2015. Safety and antitumor activity of anti-PD-1 antibody, nivolumab, in patients with platinum-resistant ovarian cancer. Journal of
Clinical Oncology 33(34):4015e4022.
Lavoué, V., Thédrez, A., Levêque, J., Foucher, F., Henno, S., Jauffret, V., et al.,
2013. Immunity of human epithelial ovarian carcinoma: the paradigm of immune suppression in cancer. Journal of Translational Medicine 11:147.
Odunsi, K., 2017. Immunotherapy in ovarian cancer. Annals of Oncology
28(Suppl 8) viii1-viii7.
Gabrilovich, D.I., 2017. Myeloid-derived suppressor cells. Cancer Immunol Res
5(1):3e8.
Bronte, V., Brandau, S., Chen, S.-H., Colombo, M.P., Frey, A.B., Greten, T.F.,
et al., 2016. Recommendations for myeloid-derived suppressor cell nomenclature and characterization standards. Nature Communications 7:12150.
Zilio, S., Seraﬁni, P., 2016. Neutrophils and granulocytic MDSC: the janus god
of cancer immunotherapy vol. 4. Basel): Vaccines, 3.
Parker, K.H., Beury, D.W., Ostrand-Rosenberg, S., 2015. Myeloid-derived
suppressor cells: critical cells driving immune suppression in the tumor
microenvironment. Advances in Cancer Research 128:95e139.
Jae Lee, W., Yi Ko, S., Mohamed, M.S., Kenny, H.A., Lengyel, E., Naora, H.,
2019. Neutrophils facilitate ovarian cancer premetastatic niche formation in
the omentum. Journal of Experimental Medicine 216(1):176e194.
Singel, K.L., Emmons, T.R., Khan, A.N.H., Mayor, P.C., Shen, S., Wong, J.T.,
et al., 2019. Mature neutrophils suppress T cell immunity in ovarian cancer
microenvironment. JCI Insight 4(5). https://doi.org/10.1172/jci.insight.122311.
PMCID: PMC6483507.
Horikawa, N., Abiko, K., Matsumura, N., Hamanishi, J., Baba, T.,
Yamaguchi, K., et al., 2017. Expression of vascular endothelial growth factor in
ovarian cancer inhibits tumor immunity through the accumulation of myeloidderived suppressor cells. Clinical Cancer Research 23(2):587e599.
Horikawa, N., Abiko, K., Matsumura, N., Baba, T., Hamanishi, J.,
Yamaguchi, K., et al., 2020. Anti-VEGF therapy resistance in ovarian cancer is
caused by GM-CSF-induced myeloid-derived suppressor cell recruitment.
British Journal of Cancer 122(6):778e788.
Godoy, H.E., Khan, A.N.H., Vethanayagam, R.R., Grimm, M.J., Singel, K.L.,
Kolomeyevskaya, N., et al., 2013. Myeloid-derived suppressor cells modulate
immune responses independently of NADPH oxidase in the ovarian tumor
microenvironment in mice. PloS One 8(7):e69631.
Cui, T.X., Kryczek, I., Zhao, L., Zhao, E., Kuick, R., Roh, M.H., et al., 2013.
Myeloid-derived suppressor cells enhance stemness of cancer cells by
inducing microRNA101 and suppressing the corepressor CtBP2. Immunity
39(3):611e621.
Di Mitri, D., Toso, A., Chen, J.J., Sarti, M., Pinton, S., Jost, T.R., et al., 2014.
Tumour-inﬁltrating Gr-1þ myeloid cells antagonize senescence in cancer.
Nature 515(7525):134e137.
Hiratsuka, S., Watanabe, A., Aburatani, H., Maru, Y., 2006. Tumour-mediated
upregulation of chemoattractants and recruitment of myeloid cells predetermines lung metastasis. Nature Cell Biology 8(12):1369e1375.
Finke, J., Ko, J., Rini, B., Rayman, P., Ireland, J., Cohen, P., 2011. MDSC as a
mechanism of tumor escape from sunitinib mediated anti-angiogenic therapy.
International Immunopharmacology 11(7):856e861.
Komura, N., Mabuchi, S., Shimura, K., Yokoi, E., Kozasa, K., Kuroda, H., et al.,
2020. The role of myeloid-derived suppressor cells in increasing cancer stem-

[31]

[32]
[33]
[34]

[35]

[36]

[37]

[38]

[39]

[40]

[41]

[42]

[43]

[44]

[45]

[46]

[47]

like cells and promoting PD-L1 expression in epithelial ovarian cancer. Cancer
Immunology Immunotherapy 69(12):2477e2499.
Khan, A.N.H., Kolomeyevskaya, N., Singel, K.L., Grimm, M.J., Moysich, K.B.,
Daudi, S., et al., 2015. Targeting myeloid cells in the tumor microenvironment
enhances vaccine efﬁcacy in murine epithelial ovarian cancer. Oncotarget
6(13):11310e11326.
Domblides, C., Lartigue, L., Faustin, B., 2018. Metabolic stress in the immune
function of T cells, macrophages and dendritic cells. Cells 7(7).
Pearce, E.L., Pearce, E.J., 2013. Metabolic pathways in immune cell activation
and quiescence. Immunity 38(4):633e643.
Hossain, F., Al-Khami, A.A., Wyczechowska, D., Hernandez, C., Zheng, L.,
Reiss, K., et al., 2015. Inhibition of fatty acid oxidation modulates immunosuppressive functions of myeloid-derived suppressor cells and enhances
cancer therapies. Cancer Immunology Research 3(11):1236e1247.
Li, W., Tanikawa, T., Kryczek, I., Xia, H., Li, G., Wu, K., et al., 2018. Aerobic
glycolysis controls myeloid-derived suppressor cells and tumor immunity via a
speciﬁc CEBPB isoform in triple-negative breast cancer. Cell Metabolism 28(1):
87e103 e6.
Jian, S.-L., Chen, W.-W., Su, Y.-C., Su, Y.-W., Chuang, T.-H., Hsu, S.-C., et al.,
2017. Glycolysis regulates the expansion of myeloid-derived suppressor cells
in tumor-bearing hosts through prevention of ROS-mediated apoptosis. Cell
Death & Disease 8(5):e2779.
Deng, Y., Yang, J., Luo, F., Qian, J., Liu, R., Zhang, D., et al., 2018. mTORmediated glycolysis contributes to the enhanced suppressive function of
murine tumor-inﬁltrating monocytic myeloid-derived suppressor cells. Cancer
Immunology Immunotherapy 67(9):1355e1364.
Wu, T., Zhao, Y., Wang, H., Li, Y., Shao, L., Wang, R., et al., 2016. mTOR
masters monocytic myeloid-derived suppressor cells in mice with allografts or
tumors. Scientiﬁc Reports 6:20250.
Al-Khami, A.A., Rodriguez, P.C., Ochoa, A.C., 2017. Energy metabolic pathways control the fate and function of myeloid immune cells. Journal of
Leukocyte Biology 102(2):369e380.
Wu, W.C., Sun, H.-W., Chen, J., OuYang, H.-Y., Yu, X.-J., Chen, H.-T., et al.,
2019. Immunosuppressive immature myeloid cell generation is controlled by
glutamine metabolism in human cancer. Cancer Immunology Research 7(10):
1605e1618.
Liao, J.B., Ovenell, K.J., Curtis, E.E.M., Cecil, D.L., Koehnlein, M.R.,
Rastetter, L.R., et al., 2015. Preservation of tumor-host immune interactions
with luciferase-tagged imaging in a murine model of ovarian cancer. Journal of
Immunotherapy Cancer 3:16.
Al-Wahab, Z., Mert, I., Tebbe, C., Chhina, J., Hijaz, M., Morris, R.T., et al.,
2015. Metformin prevents aggressive ovarian cancer growth driven by highenergy diet: similarity with calorie restriction. Oncotarget 6(13):10908e
10923.
Al-Wahab, Z., Tebbe, C., Chhina, J., Dar, S.A., Morris, R.T., Ali-Fehmi, R.,
et al., 2014. Dietary energy balance modulates ovarian cancer progression and
metastasis. Oncotarget 5(15):6063e6075.
Oh, M.-H., Sun, I.-H., Zhao, L., Leone, R.D., Sun, I.-M., Xu, W., et al., 2020.
Targeting glutamine metabolism enhances tumor-speciﬁc immunity by
modulating suppressive myeloid cells. Journal of Clinical Investigation 130(7):
3865e3884.
Mangalam, A.K., Rattan, R., Suhail, H., Singh, J., Hoda, Md N., Deshpande, M.,
et al., 2016. AMP-activated protein kinase suppresses autoimmune central
nervous system disease by regulating M1-type macrophage-Th17 Axis. The
Journal of Immunology 197(3):747e760.
Bao, X., Wu, J., Kim, .S., LoRusso, P., Li, J., 2019. Pharmacometabolomics
reveals irinotecan mechanism of action in cancer patients. The Journal of
Clinical Pharmacology 59(1):20e34.
Poisson, L.M., Suhail, H., Singh, J., Datta, I., Denic, A., Labuzek, K., et al.,
2015. Untargeted plasma metabolomics identiﬁes endogenous metabolite with

MOLECULAR METABOLISM 53 (2021) 101272 Ó 2021 The Author(s). Published by Elsevier GmbH. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
www.molecularmetabolism.com

17

Original Article

[48]

[49]

[50]

[51]

[52]

[53]

[54]

[55]

[56]

[57]
[58]

[59]

[60]

[61]

[62]

18

drug-like properties in chronic animal model of multiple sclerosis. Journal of
Biological Chemistry 290(52):30697e30712.
Dar, S., Chhina, J., Mert, I., Chitale, D., Buekers, T., Kaur, H., et al., 2017.
Bioenergetic adaptations in chemoresistant ovarian cancer cells. Scientiﬁc
Reports 7(1):8760.
Duraiswamy, J., Freeman, G.J., Coukos, G., 2013. Therapeutic PD-1 pathway
blockade augments with other modalities of immunotherapy T-cell function to
prevent immune decline in ovarian cancer. Cancer Research 73(23):6900e
6912.
Le, H.K., Graham, L., Cha, E., Morales, J.K., Manjili, M.H., Bear, H.D., 2009.
Gemcitabine directly inhibits myeloid derived suppressor cells in BALB/c mice
bearing 4T1 mammary carcinoma and augments expansion of T cells from
tumor-bearing mice. International Immunopharmacology 9(7e8):900e909.
Suzuki, E., Kapoor, V., Jassar, A.S., Kaiser, L.R., Albelda, S.M., 2005. Gemcitabine selectively eliminates splenic Gr-1þ/CD11bþ myeloid suppressor
cells in tumor-bearing animals and enhances antitumor immune activity.
Clinical Cancer Research 11(18):6713e6721.
Zeng, Y., Li, B., Liang, Y., Reeves, P.M., Qu, X., Ran, C., et al., 2019. Dual
blockade of CXCL12-CXCR4 and PD-1-PD-L1 pathways prolongs survival of
ovarian tumor-bearing mice by prevention of immunosuppression in the tumor
microenvironment. The FASEB Journal 33(5):6596e6608.
Zhu, X., Lang, J., 2017. Programmed death-1 pathway blockade produces a
synergistic antitumor effect: combined application in ovarian cancer. J Gynecol
Oncol 28(5):e64.
Seraﬁni, P., Borrello, I., Bronte, V., 2006. Myeloid suppressor cells in cancer:
recruitment, phenotype, properties, and mechanisms of immune suppression.
Seminars in Cancer Biology 16(1):53e65.
Baert, T., Vankerckhoven, A., Riva, M., Van Hoylandt, A., Thirion, G., Holger, G.,
et al., 2019. Myeloid derived suppressor cells: key drivers of immunosuppression in ovarian cancer. Frontiers in Immunology 10:1273.
Hu, C., Pang, B., Lin, G., Zhen, Y., Yi, H., 2020. Energy metabolism manipulates the fate and function of tumour myeloid-derived suppressor cells. British
Journal of Cancer 122(1):23e29.
Leone, R.D., Powell, J.D., 2020. Metabolism of immune cells in cancer. Nature
Reviews Cancer 20(9):516e531.
Yang, Y., Sauve, A.A., 2016. NAD(þ) metabolism: bioenergetics, signaling and
manipulation for therapy. Biochimica et Biophysica Acta 1864(12):1787e
1800.
Vatrinet, R., Leone, G., De Luise, M., Girolimetti, G., Vidone, M., Gasparre, G.,
et al., 2017. The alpha-ketoglutarate dehydrogenase complex in cancer
metabolic plasticity. Cancer & Metabolism 5:3.
Young, A., Gardiner, D., Brosnan, M.E., Brosnan, J.T., Mailloux, R.J., 2017.
Physiological levels of formate activate mitochondrial superoxide/hydrogen
peroxide release from mouse liver mitochondria. FEBS Letters 591(16):2426e
2438. https://doi.org/10.1002/1873-3468.12777. PMID: 28771687.
Srivastava, M.K., Zhu, L., Harris-White, M., Kar, U.K., Huang, M.,
Johnson, M.F., et al., 2012. Myeloid suppressor cell depletion augments
antitumor activity in lung cancer. PloS One 7(7):e40677.
Stromnes, I.M., Brockenbrough, J.S., Izeradjene, K., Carlson, M.A., Cuevas, C.,
Simmons, R.M., et al., 2014. Targeted depletion of an MDSC subset unmasks

[63]

[64]

[65]

[66]

[67]

[68]
[69]

[70]

[71]
[72]
[73]

[74]
[75]

[76]

[77]

pancreatic ductal adenocarcinoma to adaptive immunity. Gut 63(11):1769e
1781.
Bak, S.P., Alonso, A., Turk, M.J., Berwin, B., 2008. Murine ovarian cancer vascular
leukocytes require arginase-1 activity for T cell suppression. Molecular Immunology 46(2):258e268.
Conejo-Garcia, J.R., Benencia, F., Courreges, M.-C., Kang, E., MohamedHadley, A., Buckanovich, R.J., et al., 2004. Tumor-inﬁltrating dendritic cell
precursors recruited by a beta-defensin contribute to vasculogenesis under the
inﬂuence of Vegf-A. Nature Medicine 10(9):950e958.
Yang, R., Cai, Z., Zhang, Y., Yutzy, W.H., Roby, K.F., Roden, R.B.S., 2006.
CD80 in immune suppression by mouse ovarian carcinoma-associated Gr1þCD11bþ myeloid cells. Cancer Research 66(13):6807e6815.
Galliverti, G., Wullschleger, S., Tichet, M., Murugan, D., Zangger, N.,
Horton, W., et al., 2020. Myeloid cells orchestrate systemic immunosuppression, impairing the efﬁcacy of immunotherapy against HPV(þ) cancers.
Cancer Immunology Research 8(1):131e145.
Walankiewicz, M., Grywalska, E., Polak, G., Kotarski, J., Siwicka-Gieroba, D.J.,
Rolinski, J., 2017. Myeloid-derived suppressor cells in ovarian cancer: friend
or foe? Central European Journal of Immunology 42(4):383e389.
Kedia-Mehta, N., Finlay, D.K., 2019. Competition for nutrients and its role in
controlling immune responses. Nature Communications 10(1):2123.
Reinfeld, B.I., Madden, M.Z., Wolf, M.M., Chytil, A., Bader, J.E.,
Patterson, A.R., et al., 2021. Cell-programmed nutrient partitioning in the
tumour microenvironment. Nature 593(7858):282e288.
Al-Khami, A.A., Zheng, L., Del Valle, L., Hossain, F., Wyczechowska, D.,
Zabaleta, J., et al., 2017. Exogenous lipid uptake induces metabolic and
functional reprogramming of tumor-associated myeloid-derived suppressor
cells. Oncoimmunology 6:e1344804.
Altman, B.J., Stine, Z.E., Dang, C.V., 2016. From Krebs to clinic: glutamine
metabolism to cancer therapy. Nature Reviews Cancer 16(11):749.
Yang, L., Venneti, S., Nagrath, D., 2017. Glutaminolysis: a hallmark of cancer
metabolism. Annual Review of Biomedical Engineering 19:163e194.
Martinez-Outschoorn, U.E., Peiris-Pagés, M., Pestell, R.G., Sotgia, F.,
Lisanti, M.P., 2017. Cancer metabolism: a therapeutic perspective. Nature
Reviews Clinical Oncology 14(1):11e31.
Vander Heiden, M.G., DeBerardinis, R.J., 2017. Understanding the intersections between metabolism and cancer biology. Cell 168(4):657e669.
Remacha, L., Pirman, D., Mahoney, C.E., Coloma, J., Calsina, B., CurrásFreixes, M., et al., 2019. Recurrent germline DLST mutations in individuals
with multiple pheochromocytomas and paragangliomas. The American Journal
of Human Genetics 104(5):1008e1010.
Anderson, N.M., Li, D., Peng, H.L., Laroche, F.J.F., Mansour, M.R., Gjini, E.,
et al., 2016. The TCA cycle transferase DLST is important for MYC-mediated
leukemogenesis. Leukemia 30(6):1365e1374. https://doi.org/10.1038/
leu.2016.26. PMID: 26876595 PMCID: PMC4889531.
Furusawa, A., Miyamoto, M., Takano, M., Tsuda, H., Song, Y.S., Aoki, D.,
et al., 2018. Ovarian cancer therapeutic potential of glutamine depletion based
on GS expression. Carcinogenesis 39(6):758e766.

MOLECULAR METABOLISM 53 (2021) 101272 Ó 2021 The Author(s). Published by Elsevier GmbH. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
www.molecularmetabolism.com

